INSMED Inc (INSM) — SEC Financial Statements & Analysis

INSMED Inc (INSM) is a pharmaceutical preparations company, incorporated in VA. INSMED Inc trades on Nasdaq as: INSM. INSMED Inc (INSM)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, INSMED Inc carries a market cap of $23.17B, a P/E ratio of -26.48x, a P/B ratio of 30.59x, a P/S ratio of 20.37x, an enterprise value of $23.18B, and an EV/EBITDA multiple of -27.98x. On profitability, it posts a gross margin of 83.46%, an operating margin of -73.89%, a net margin of -76.94%, a Return on Equity (ROE) of -87.22%, a Return on Assets (ROA) of -38.20%, and a Return on Invested Capital (ROIC) of -129.57%. Per share, it reports EPS of $-4.03, diluted EPS of $-4.03, free cash flow per share of $-3.72, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 185.76% year-over-year, net income growth of -15.38% year-over-year, and EPS growth of -26.30% year-over-year. On the balance sheet, it maintains a current ratio of 3.72x, a quick ratio of 3.14x, working capital of $1.20B, a debt-to-equity ratio of 1.78x, a debt ratio of 0.64, an interest coverage ratio of -10.34x, free cash flow of $-807.67M (TTM), and net debt of $2.30M. Figures sourced from SEC EDGAR.

Market Cap

$23.17B

P/E TTM

-26.48x

EPS TTM

$-4.03

P/B TTM

30.59x

ROE TTM

-87.22%

ROA TTM

-38.20%

Debt To Equity

1.78x

Free Cash Flow TTM

$-807.67M

Net Revenue TTM Growth 1Y

185.76%

Data as of 2026-06-30 · Source: SEC EDGAR